Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05087420
Other study ID # MIGinPOL2021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2021
Est. completion date April 30, 2022

Study information

Verified date May 2022
Source Swiat Zdrowia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A survey of Polish respondents will aim to define migraine characteristics in Polish subjects. To achieve this, a structured questionnaire based mainly on American Migraine Prevalence and Prevention Study has been prepared to serve as a tool for data extraction. The obtained data should allow for defining disease parameters, burden and received treatments. Additionally questions regarding patients rhinological symptoms and COVID-19-related history were included.


Recruitment information / eligibility

Status Completed
Enrollment 2800
Est. completion date April 30, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - consent to participate in the study Exclusion Criteria: - responses missing in questionnaire

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Poland Marcin Straburzynski Dzwierzuty Warminsko-mazurskie
Poland Department of Neurology, Wroclaw Medical University Wroclaw

Sponsors (2)

Lead Sponsor Collaborator
Swiat Zdrowia Wroclaw Medical University

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Headache phenotype Classification of reported headache according to International Classification of Headache Disorders in the preceding year
Primary Migraine burden Consequences of the disease measured by the Migraine Disability Assessment Test in the preceding year
Secondary Monthly headache days Number of days per month in the preceding month
Secondary Monthly headache days Number of days per year in the preceding year
Secondary Time from last headache professional consultation Number of months in the preceding 10 years
Secondary Migraine diagnosed by headache professional yes/no in the preceding 10 years
Secondary Age at diagnosis years from the onset of headache (time frame up to 99 years)
Secondary Comoribidities Disease according to International Classsification of Disease 10 in the preceding year
Secondary Type of previous headache professional consultation Name of headache profession/speciality in the preceding 10 years
Secondary Number of consultations in the last year Number 0-100 in the last 12 months
Secondary Number of consultations in the last year because of headaches Number 0-100 in the last 12 months
Secondary Number of days spent in hospital in the last year because of headaches Number 0-100 in the last 12 months
Secondary Acute treatment used Name of abortive medication in the preceding 10 years
Secondary Preventive treatment used Name of abortive medication in the preceding 10 years
Secondary Acute treatment frequency Number of days per month in the last 3 months
Secondary Preventive treatment frequency Number of months form the last dose in the last 12 months
Secondary Preventive treatment effectiveness Likert scale in the last 12 months
Secondary Employment Type of employment in the last 12 months
Secondary Time spent at work Number of hours per week in the last 12 months
Secondary Work absence due to headache Number of days per month in the last month
Secondary Presenteeism Number of days per month in the last month
Secondary PHQ-9 Patient Health Questionnaire Number in the last 2 weeks
Secondary Sinus headache Number of days in the last 3 months
Secondary Sinonasal symptoms accompanying headache Type of symptoms in the last 12 months
Secondary Sinonasal symptoms not associated with headache Type of symptom in the last 12 months
Secondary COVID-19 association with headache Likert scale in the last 2 years
Secondary COVID-19 vaccine association with headache Likert scale in the last year
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A

External Links